Company Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
0.8499 ^USD	-2.31%		-6.09%	-19.06%

May. 13	Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 01	Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patientâs own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patientâs own red blood cells. The Companyâs Phase III lead asset, EryDex, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patientâs own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules, as well as biologics.

Number of employees: 32

Managers	Title	Age	Since
Dirk Thye CEO	Chief Executive Officer	54	22-05-18
Brendan Hannah DFI	Director of Finance/CFO	39	22-04-30
Charles Ryan PSD	President	60	23-08-31
Maureen M. Roden CTO	Chief Tech/Sci/R&D Officer	-	22-05-31
Stacy Roughan IRC	Investor Relations Contact	-	-
Gary Ward PRN	Corporate Officer/Principal	-	22-07-31
Mary Ellen Sillivos HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Una Ryan BRD	Director/Board Member	82	18-02-28
Luca Benatti BRD	Director/Board Member	63	23-10-22
Dirk Thye CEO	Chief Executive Officer	54	22-05-18
David Lamond CHM	Chairman	49	15-11-30
Rajiv Patni BRD	Director/Board Member	55	Feb. 14
Christopher Senner BRD	Director/Board Member	56	19-02-28
Margaret McLoughlin BRD	Director/Board Member	61	15-11-30
June Bray BRD	Director/Board Member	70	22-06-08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	43,215,233	37,537,793 ( 86.86 %)	0	86.86 %

Name	Equities	%	Valuation
David Lamond 10.14 %	4,384,096	10.14 %	5 M $
Tang Capital Management LLC 6.821 %	2,947,652	6.821 %	3 M $
Genextra SpA 5.845 %	2,525,950	5.845 %	3 M $
Sofinnova Partners SAS 5.040 %	2,178,150	5.040 %	2 M $
Vanguard Global Advisers LLC 2.618 %	1,131,530	2.618 %	1 M $
EPIQ Capital Group LLC 1.957 %	845,773	1.957 %	871 146 $
Dirk Thye 1.595 %	689,441	1.595 %	710 124 $
Renaissance Technologies LLC 1.204 %	520,100	1.204 %	535 703 $
Brad Leonard 0.8680 %	375,100	0.8680 %	386 353 $
BlackRock Advisors LLC 0.7586 %	327,836	0.7586 %	337 671 $

Quince Therapeutics, Inc.

611 Gateway Boulevard Suite 273

94080, South San Francisco

http://quincetx.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUINCE THERAPEUTICS, INC.	-19.06%	36.73M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research